Role of non-invasive testing in the staging, prognostic assessment, and treatment monitoring of metabolic associated fatty liver disease
10.3760/cma.j.cn501113-20250604-00218
- VernacularTitle:无创检测在代谢相关脂肪性肝病分期、预后评估及治疗监测中的作用
- Author:
Wong Vincent WAI-SUN
1
;
Ruixu YANG
;
Jiangao FAN
Author Information
1. 中国香港中文大学医学院内科及药物治疗学系医学数据分析中心，香港
- Publication Type:Journal Article
- Keywords:
Fatty liver;
Metabolic associated fatty liver disease;
Non-invasive diagnosis;
Staging;
Evaluation
- From:
Chinese Journal of Hepatology
2025;33(9):826-833
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease (MAFLD) has become one of the leading causes of cirrhosis and hepatocellular carcinoma. Therefore, identifying high-risk MAFLD patients accurately and providing monitoring and treatment is crucial.Invasive liver biopsy has inherent defects such as high costs, low patient acceptance, and significant inconsistencies in readings between individual pathologists. Non-invasive testing technologies have become a core measure in the management of MAFLD. This paper summarizes and discusses the latest application progress of non-invasive testing technologies in the field of MAFLD and explores the key aspects that urgently need improvement, with the aim of providing clinical doctors with references for effectively assessing the progression trends of MAFLD patients and implementing intervention treatments.
